Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis

A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis

NCT04664959 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis

NCT00089791 ·Status: COMPLETED ·Phase: PHASE3

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

NCT02051218 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

NCT01732770 ·Status: COMPLETED ·Phase: PHASE4

A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

NCT05405725 ·Status: COMPLETED ·Phase: PHASE3

Denosumab Safety Assessment in Multiple Observational Databases

NCT02520362 ·Status: COMPLETED

Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density

NCT00043186 ·Status: COMPLETED ·Phase: PHASE2

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

NCT03432533 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

NCT01575834 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

NCT05352516 ·Status: COMPLETED ·Phase: PHASE3

Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes

NCT06154707 ·Status: RECRUITING ·Phase: PHASE3

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

NCT02049866 ·Status: COMPLETED ·Phase: PHASE2

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

NCT03974100 ·Status: COMPLETED ·Phase: PHASE3

A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density

NCT00515463 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures

NCT06720350 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis

NCT05419427 ·Status: RECRUITING ·Phase: PHASE3

A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis

NCT04757376 ·Status: COMPLETED ·Phase: PHASE3

Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis

NCT00523341 ·Status: COMPLETED ·Phase: PHASE3

Denosumab Adherence Preference Satisfaction Study

NCT00518531 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

NCT06332014 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

A Study of LY2541546 in Women With Low Bone Mineral Density

NCT01144377 ·Status: COMPLETED ·Phase: PHASE2

Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis

NCT00980174 ·Status: COMPLETED ·Phase: PHASE3

A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density

NCT00293813 ·Status: COMPLETED ·Phase: PHASE2

A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China

NCT06588153 ·Status: RECRUITING ·Phase: PHASE4

Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index

NCT02435147 ·Status: COMPLETED